Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Best Practices Workshop: Assessing the Potential for Chemically Induced Allergic Contact Dermatitis Final Documents
January 20, 2011

Best Practices Workshop: Assessing the Potential for Chemically Induced Allergic Contact Dermatitis Meeting Materials
January 20, 2011

Best Practices Workshop: Assessing the Potential for Chemically Induced Allergic Contact Dermatitis Presentations
January 20, 2011

Introduction and Public Health Impact of Chemically Induced Allergic Contact Dermatitis (ACD)
RADM William Stokes, DVM, U.S. Public Health Service, NICEATM, NIEHS

Review of Alternative Test Methods and Integrated Strategies for ACD Hazard Assessments
Joanna Matheson, PhD, Consumer Product Safety Commission

Study Director and IACUC Responsibilities: Consideration of Available Reduction, Refinement, and Replacement Alternative Test Methods
Jodie Kulpa-Eddy, DVM, Animal and Plant Health Inspection Service, Department of Agriculture

Conducting and Interpreting the Murine Local Lymph Node Assay
Michael Woolhiser, PhD, The Dow Chemical Co.

The Reduced Murine Local Lymph Node Assay — Validation Status and Appropriate Use
David Allen, PhD, ILS, Inc., Contractor Supporting NICEATM

The Murine Local Lymph Node Assay: BrdU-ELISA
Judy Strickland, PhD, ILS, Inc., Contractor Supporting NICEATM
View video on cell suspension to accompany slide 5 [WMV]
View video on supernatant removal to accompany slide 6 [WMV]
Captioned and narrated versions of videos available on archived webcast: begin at 120 minutes

The Murine Local Lymph Node Assay: DA
Eleni Salicru, PhD, ILS, Inc., Contractor Supporting NICEATM

Application of Peptide Reactivity for Screening ACD Hazard Potential
Darrell Boverhof, PhD, The Dow Chemical Co.

Roundtable Discussion: Regulatory Agency Requirements and Acceptable Alternative Test Methods for ACD Hazard Assessments

Alternative Test Methods for ACD Hazard Assessment: Case Studies in Breakout Groups
View case study presentations and discussion summaries

New Models in the Validation Pipeline for ACD Hazard Testing